All pharmamanufacturing.com Blogs
Boehringer Ingelheim's commitment to educating the Hispanic community on the impact of chronic disease is particularly noteworthy.
Praxair, Inc. announced it’s been listed on the STOXX Global ESG Leaders Index and STOXX North America ESG Leaders 50 for the third consecutive year.
A fast-growing petition is asking the FDA to grant 12 year old McKenzie Lowe of New Hampshire with “compassionate use” access to Antineoplastons therapy, a treatment that could save McKenzie from her inoperable brain tumor (DIPG).
I apologize if some of my columns over the years have seemed a bit negative or critical. As a publication, we started up at a time when thought leaders pointed out the seemingly limitless potential to improve and modernize manufacturing.
Pop quiz! Where did the following snippets from FDA citations come from? (Winner gets a free coffee mug, runner up gets two -:))Contamination during the manufacture of serum injectables?Failure to measure or account for endotoxins? Failure to respond to adverse patient reactions? Presence of vermin and unsanitary conditions at the...
This just in from FDA....
We wanted to criticize, in as forceful and graphic a way as possible, the cynical attitude of the compounding facility management, to call attention to the disgraceful conditions that were found at many of the compounding facilities that were inspected, and also to draw some attention to the political situation (e.g.
Just received confirmation of last post. Here's the official letter announcing changes from CDER Director, Dr. Janet Woodcock
Haven't confirmed any of this yet, but just heard rumors of change, and another 'superoffice' restructuring at FDA. Apparently, within the new framework, the Office of Generic Drugs will become a "superoffice", OPS will be no more, while OMPQ, ONDQA and OBP will report to OPQ. The Office of Compliance...
Four Reasons Why You Should Do it, Three Reasons Why You're Not